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Shiga toxins (Stxs) are bacterial cytotoxins produced by the enteric pathogens Shigella dysenteriae serotype
1 and some serotypes of Escherichia coli that cause bacillary dysentery and hemorrhagic colitis, respectively. To
date, approaches to studying the capacity of Stxs to alter gene expression in intoxicated cells have been limited
to individual genes. However, it is known that many of the signaling pathways activated by Stxs regulate the
expression of multiple genes in mammalian cells. To expand the scope of analysis of gene expression and to
better understand the underlying mechanisms for the various effects of Stxs on host cell functions, we carried
out comparative microarray analyses to characterize the global transcriptional response of human macro-
phage-like THP-1 cells to Shiga toxin type 1 (Stx1) and lipopolysaccharides. The data were analyzed by using
a rigorous combinatorial approach with three separate statistical algorithms. A total of 36 genes met the
criteria of upregulated expression in response to Stx1 treatment, with 14 genes uniquely upregulated by Stx1.
Microarray data were validated by real-time reverse transcriptase PCR for genes encoding early growth
response 1 (Egr-1) (transcriptional regulator), cyclooxygenase 2 (COX-2; inflammation), and dual specificity
phosphatase 1 (DUSP1), DUSP5, and DUSP10 (regulation of mitogen-activated protein kinase signaling).
Stx1-mediated signaling through extracellular signal-regulated kinase 1/2 and Egr-1 appears to be involved in
the increased expression and production of the proinflammatory mediator tumor necrosis factor alpha.
Activation of COX-2 is associated with the increased production of proinflammatory and vasoactive eicosanoids.
However, the capacity of Stx1 to increase the expression of genes encoding phosphatases suggests that mechanisms
to dampen the macrophage proinflammatory response may be built into host response to the toxins.
Shiga toxins (Stxs), also known as verotoxins, are genetically
and functionally related bacterial cytotoxins primarily pro-
duced by enteric pathogens. Shigella dysenteriae serotype 1
expresses Shiga toxin, while Stx-producing Escherichia coli
(STEC) may produce one or more antigenically related toxins
categorized as Shiga toxin type 1 (Stx1) or Stx2 (30, 44). Stx-
producing bacteria continue to constitute a global health prob-
lem. When contaminated food or water is ingested, it can result
in bloody diarrhea and potentially lead to life-threatening com-
plications such as hemolytic-uremic syndrome (HUS) and cen-
tral nervous system complications (36, 46). Stxs have an AB5
structure, consisting of a single enzymatic A-subunit in nonco-
valent association with a pentameric ring of B subunits (9–10).
The toxins bind the glycolipid receptor globotriaosyl ceramide
(Gb3) on the cell surface by interaction with the toxin B sub-
units. They are then internalized to early endosomes and trans-
ported through the trans-Golgi network and Golgi apparatus to
reach the endoplasmic reticulum (ER) (34). In the ER, the
toxin A subunit is proteolytically processed and the A1 frag-
ment retrotranslocates into the cytoplasm (45). Once in the
cytoplasm, the A1 fragment catalytically cleaves a single ade-
nine residue in the 28S rRNA component of 60S eukaryotic
ribosomal subunits, resulting in protein synthesis inhibition (40).
Despite possessing the capacity to inactivate ribosomes, Stxs
have also been shown to have different biological effects on
different cell types. Stxs can activate host cell signaling path-
ways that result in cytokine and chemokine expression (5, 8,
13–14, 38). It has been shown that interleukin-1 (IL-1) and
tumor necrosis factor alpha (TNF-) sensitize endothelial cells
to the action of Stx in vitro by increasing Gb3 expression (43,
54). Therefore, the innate immune response elicited by Stxs
may contribute to the development of vascular lesions by sen-
sitizing endothelial cells to the action of toxins (37). We have
found that when macrophage-like THP-1 cells are stimulated
with Stx1, they secrete TNF-, IL-1, IL-6, and a number of
CC and CXC chemokines. Alterations in expression of cyto-
kines and chemokines by Stxs are regulated through transcrip-
tional and translational mechanisms. Transcriptional regula-
tion involves prolonged activation of stress-associated protein
kinases JNK (c-Jun N-terminal kinases) and p38, transient
activation of mitogen-activated protein kinases (MAPKs) ex-
tracellular signal-activated kinase 1/2 (ERK1/2), and activation
of transcription factors NF-B (nuclear factor-B) and activa-
tion protein 1 (AP-1). Translational control involves, in part,
stabilization of mRNA transcripts and activation of eukaryotic
translation initiation factors (5, 13–14, 38–39, 49).
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Our approach to studying the capacity of Stxs to activate
cytokine and chemokine gene expression to date has been
limited to these individual genes. However, the myriad signal-
ing pathways activated by Stxs may potentially regulate the
expression of large numbers of genes (6). Therefore, we carried
out comparative microarray analyses to help explore global tran-
scriptional responses of macrophage-like THP-1 cells treated with
Stx1 or the well-characterized bacterial outer membrane constit-
uent lipopolysaccharides (LPS). Previous studies have explored
global gene expression induced by Stx2 in whole murine kid-
neys (20) and by Stx1 and Stx2 in human vascular endothelial
cells (27). Our findings support these earlier studies in that Stxs
elicited limited, but reproducible, changes in gene expression
in macrophage-like THP-1 cells. The major category of genes
that we found upregulated by Stx1 treatment of macrophage-
like cells encode transcription regulatory factors, although
genes involved in signaling, apoptosis, and inflammation were
also activated.
MATERIALS AND METHODS
Reagents. Antibodies directed against human early growth factor 1 (Egr-1),
cyclooxygenase 2 (COX-2), and actin were obtained from Cell Signaling Tech-
nology, Beverly, MA. ERK1/2 inhibitor PD 98059 was obtained from Calbio-
chem (La Jolla, CA). Except where noted, all other reagents were purchased
from Sigma Chemical Co. (St. Louis, MO).
Toxins. Stx1 used in the present study was prepared as previously described
(47). Briefly, Stx1 was purified from cell lysates prepared from E. coli
DH5(pCKS112) by sequential ion exchange and chromatofocusing chromatog-
raphy. Purity of toxins preparations was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with silver staining and West-
ern blot analysis with anti-Stx1 antibodies. Toxin preparations contained 0.1 ng
of endotoxin per ml as determined by the Limulus amoebocyte lysate assay
(Associates of Cape Cod, Falmouth, ME). Purified LPS derived from the en-
terohemorrhagic E. coli serotype O111 was purchased from Sigma Chemical Co
(St. Louis, MO).
Cell lines. The human myelogenous leukemia cell line THP-1 (53) was ob-
tained from the American Type Culture Collection, Manassas, VA. The cells
were maintained in RPMI 1640 (Gibco-BRL, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS; HyClone Laboratories, Logan, UT), peni-
cillin (100 U/ml), and streptomycin (100 g/ml) at 37°C in 5% CO2 in a humid-
ified incubator.
Macrophage differentiation and stimulation. The mature macrophage-like
state was induced by treating THP-1 cells (106 cells/ml) for 48 h with phorbol
12-myristate 13 acetate (PMA) at 50 ng/ml. Plastic-adherent cells were washed
twice with cold, sterile Dulbecco phosphate-buffered saline (PBS), and incubated
with fresh RPMI 1640 lacking PMA but containing 10% FBS, penicillin (100
U/ml), and streptomycin (100 g/ml). The medium was then changed every 24 h
for 3 additional days. Experiments were performed on the fourth day after
removal of PMA. To isolate total RNA, differentiated THP-1 cells (2.5  106
cells/ml) were washed once with cold PBS and fresh RPMI 1640 medium con-
taining 10% FBS, with no antibiotics added prior to stimulation with Stx1 (400
ng/ml) or LPS (200 ng/ml) for various times. We have previously demonstrated
that these stimulant doses produced maximal cytokine protein secretion in dif-
ferentiated THP-1 cells in vitro (38). To prepare cellular lysates, THP-1 cells
(2.5  106 cells/ml) were serum starved by growth in RPMI 1640 medium
containing 0.5% FBS, penicillin (100 U/ml), and streptomycin (100 g/ml) for
18 h to reduce background kinase signaling. Cells were washed as described
above and stimulated with Stx1 (400 ng/ml) or LPS (200 ng/ml) in RPMI 1640
plus 0.5% FBS for various times. For MAPK inhibitor studies, cells were treated
with the ERK1/2 inhibitor (PD98059; 50 M) for 1 h prior to challenge with Stx1
(400 ng/ml) in RPMI 1640–10% FBS for various times.
Microarray analysis. Total RNA from macrophage-like THP-1 cells was iso-
lated by using the RNAqueous kit (Ambion, Austin, TX), and 20 g of total
RNA was processed for microarray analysis. Briefly, cDNA synthesis, in vitro
transcription, labeling and fragmentation to produce the oligonucleotide probes
were performed according to the GeneChip manufacturer’s instructions (Af-
fymetrix, Santa Clara, CA). The probes were first hybridized to a test array
(Affymetrix) and then to the GeneChip human genome HG-U133 Array (con-
taining 54,675 probe sets representing more than 39,000 transcripts derived from
33,000 well-substantiated human genes) using the GeneChip Hybridization
Oven 640. The chips were washed in a GeneChip Fluidics Station 400 (Af-
fymetrix), and the were results visualized with a Gene Array scanner using
Affymetrix software. The data were analyzed by using the following software:
GeneSifter (VizX Labs, Seattle, WA), Significance Analysis of Microarrays
(SAM; Stanford University, Stanford, CA), and Spotfire DecisionSite 9.0 (Spot-
fire, Inc., Somerville, MA). Genes that were considered as significantly differen-
tially expressed between untreated and Stx1-treated cells were identified sepa-
rately using each of the three analysis methods. Those deemed as uniquely
altered by Stx1 were not differentially expressed between untreated and LPS-
treated cells using any of the three different analysis techniques. Raw and pro-
cessed data (a total of nine arrays) were deposited in the Gene Expression
Omnibus (GEO) online (www.ncbi.nlm.nih.gov/geo) database (accession no.
GSE19315).
Real-time reverse transcription-PCR (RT-PCR). Total RNA was isolated by
using a TRIzol Plus kit (Invitrogen, Carlsbad, CA) with an RNase-free DNase
(Invitrogen) treatment according to the manufacturer’s instructions. RNA was
reverse transcribed to cDNA by using a high-capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, Foster City, CA), and real-time PCR was per-
formed on the resulting cDNAs using SYBR green I double-stranded DNA
binding dye (Applied Biosystems). Real-time specific primer sequences for
Egr-1, COX-2, dual-specificity phosphatase 1 (DUSP1), DUSP5, and DUSP10,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown in Table 1
(13, 15–16, 22, 26, 57). The real-time PCRs were carried out with 100 nM
concentrations (each) of forward and reverse primers in a final volume of 25 l.
To control for the presence of contaminating DNA in the real-time PCRs,
reverse transcriptase-negative reactions were included. Nontemplate controls
were run to test for DNA-contaminated primers. Real-time reactions were run
and analyzed by using an ABI Prism 7500 sequence detection system (Applied
Biosystems). Dissociation curves for PCR samples were made to guarantee
amplification of the correct genes. The amount of mRNA fold induction was
determined from the change in threshold cycle (CT) values normalized for
GAPDH expression and then normalized to the value derived from cells at time
zero prior to medium change or treatment. Statistical analyses of real-time PCR
data were performed using CT values.
Preparation of cellular lysates. Cells were harvested and lysed at 4°C in
modified radioimmunoprecipitation assay buffer (1.0% Nonidet P-40, 1.0% so-
dium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 0.25 mM sodium
pyrophosphate, sodium vanadate and sodium fluoride [2 mM each], 10 g of
aprotinin/ml, 1.0 g of leupeptin and pepstatin/ml, and 200 mM phenylmeth-
ylsulfonyl fluoride). Extracts were collected and cleared by centrifugation at
TABLE 1. Real-time PCR primersa
Target Referenceb Orientationc Primer sequence (5	–3	)
Egr1 16 F GCCTGCGACATCTGTGGAA
R GCCGCAAGTGGATCTTGGTA
COX2d F GAATCATTCACCAGGCAAATTG
R TCTGTACTGCGGGTGGAACA
DUSP1 26 F GGCCCCGAGAACAGACAAA
R GTGCCCACTTCCATGACCAT
DUSP5 15 F CATCAGCCAGTGTGGAAAACC
R GGCCACCCTGGTCATAAGC
DUSP10 11 F AAGAGGCTTTTGAGTTCAT
TGAG
R CAAGTAAGCGATGACGATGG
GAPDH 13 F CAACGGATTTGGTCGTATTGG
R GGCAACAATATCCACTTTACCA
GAGT
TNF- 57 F CCAGGCAGTCAGATCATCTTCTC
R AGCTGGTTATCTCTCAGCTCCAC
a Primers were synthesized by Integral DNA Technologies (Coralville, IA).
b Published reference for each primer set.
c F, forward; R, reverse.
d Designed using IDT’s Primer Quest.
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15,000  g for 10 min. Cleared extracts were stored at 
80°C until further use
for Western blot analysis.
Western blot analysis. Cell extracts prepared from stimulated THP-1 cells
were used for determination of protein concentration using the Micro BCA
protein assay kit (Pierce, Rockford, IL). Equal amounts of protein (100 g per
gel lane) were separated by SDS-PAGE using 8% acrylamide gels and trans-
ferred to nitrocellulose membranes, which were blocked with 5% nonfat milk
prepared in Tris-buffered saline (TBS)/Tween 20 (200 mM Tris [pH 7.6], 1.38 M
NaCl, 0.1% Tween 20) and incubated overnight at 4°C with various primary
antibodies specific for Egr-1, COX-2, and actin in 5% bovine serum albumin
made with TBS–0.1% Tween 20. Membranes were then incubated with second-
ary antibody (rabbit immunoglobulin G coupled to horseradish peroxidase) for
1 h at room temperature. Bands were visualized using the Western Lightning
chemiluminescence system (NEN-Perkin Elmer, Boston, MA). The intensities of
protein bands captured on autoradiography film were quantitated using ImageJ
software (Bio-Rad, Hercules, CA). The fold induction was calculated as stimu-
lated protein band intensity values divided by unstimulated control protein band
intensity values after normalizing for loading controls. The data shown are from
at least three independent experiments.
Measurement of eicosanoids. Differentiated THP-1 cells (2.5  106 cells/ml)
were treated with Stx1 (400 ng/ml) for various time points. Supernatants were
then collected to measure soluble eicosanoid production. Prostaglandin E2
(PGE2) concentrations were determined by using a PGE2 EIA kit (Assay De-
signs, Ann Arbor, MI), and thromboxane B2 (TXB2) was measured by using a
TXB2 enzyme immunoassay kit (Cayman Chemical Company, Ann Arbor, MI)
according to the manufacturer’s instructions. PGE2 and TXB2 standards were
provided with each kit and used in each assay. Absorbance was measured at 450
nm (PGE2) or 420 nm (TXB2) by using an enzyme-linked immunosorbent assay
(ELISA) reader (Dynatech MR5000, Chantilly, VA). The results were expressed
as pg of PGE2 or TXB2/ml in supernatants. The sensitivities of these assays were
8 pg/ml (PGE2) and 11 pg/ml (TXB2).
Statistical analysis. Quantitative RT-PCR, ELISA, and Western blot data
were analyzed by one-way analysis of variance (ANOVA) with Dunnett’s post
test, and quantitative RT-PCR data of ERK1/2 inhibitor-treated cells were
analyzed by two-way ANOVA with the Bonferroni post test using GraphPad
Prism version 5.00 for Windows (San Diego, CA).
RESULTS
Stx induces upregulation of gene transcription in macro-
phage-like THP-1 cells. In three separate experiments, THP-1
cells were untreated or treated with Stx1 (400 ng/ml) or LPS
(200 ng/ml) for 6 h. RNA was then isolated and applied to
HG-U133 GeneChips. The data were analyzed by using a com-
binatorial approach utilizing different software programs, sta-
tistical algorithms, and biological relevance measured in order
to obtain the most robust list of genes representing highly
consistent and reproducible results. Signal values were aver-
aged, and the fold change determined using GeneSifter. Genes
were deemed as significantly differentially expressed if the ob-
served average fold change was at least 1.5 and the Benjamini
and Hochberg-corrected P value was 0.05. For Stx1-treated
cells, SAM analysis (Stanford University) was also performed,
using the two-class unpaired option with the additional criteria
of at least 1.5-fold differential expression. Individual pairwise
comparisons were also carried out by using Spotfire Decision-
Site 9.0 software; a fold change of at least 1.5 was expected. For
LPS-treated samples, only the average fold change and Stu-
dent t test (obtained using GeneSifter) were used to determine
significance. Hierarchical clustering of the normalized signal
values corroborated the statistical analyses (Fig. 1A). Each of
the sample types (untreated cells [control], LPS-treated cells,
and Stx1 treated cells) clustered together and apart from the
other two sample types. LPS- and Stx1-treated cells were more
similar to each other than to untreated control cells. Signifi-
cantly, although we identified genes regulated by both Stx1 or
LPS (depicted by the color red in lanes labeled LPS1 to LPS3
FIG. 1. (A) Hierarchical clustering (performed using Spotfire DecisionSite) shows subsets of genes that are specifically upregulated in response
to LPS or Stx1 (marked on the sides by a blue-green line) or are coregulated by LPS and Stx1. Bright green indicates very low signal values, bright
red represents very high signal values, and black represents median signal values. C, control (untreated); LPS, LPS-treated; ST, Stx1-treated cells.
Each replicate is indicated by the numbers 1 to 3. Each of the sample types (C1 to -3, LPS1 to -3, and ST1 to -3) clustered together and apart from
the other two sample types, and LPS- and Stx1-treated macrophages were more similar to each other than to untreated control cells. One subset
of genes (indicated by the blue-green line on either side) was specifically upregulated in response to Stx1 treatment but not LPS treatment.
(B) Venn diagram showing upregulated gene probes after Stx or LPS treatment. GeneSifter software was used to perform RMA normalization,
followed by pairwise comparisons and Student t test with a Benjamini and Hochberg correction; the cutoffs used were a fold change of at least 1.5
and an adjusted P value of 0.05.
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and ST1 to ST3 in Fig. 1A), we also identified genes uniquely
regulated by Stx1 (depicted by the color red only in lanes
labeled ST1 to ST3) or LPS (red only in lanes labeled LPS1 to
LPS3). Using only GeneSifter, 2,615 probes were found to be
upregulated by LPS treatment, 42 by both LPS and Stx1 and 82
by Stx1 alone as shown in Fig. 1B. Further statistical analysis of
Stx1 treated samples showed that 52 probe sets (representing
36 genes) were significantly differentially expressed between
untreated and Stx1 treated macrophage-like THP-1 cells. Of
these 52 probe sets, 31 were also altered by LPS treatment; the
remaining 21 probe sets represented 14 different genes that
were specifically altered by Stx1 treatment (i.e., were not al-
tered by LPS treatment). Interestingly, there were no genes
downregulated by Stx1 treatment across all three replicate
samples. The 36 genes significantly upregulated by Stx1 treat-
ment compared to untreated controls (the complete list is
shown in Table S1 in the supplemental material) were then
categorized by function. As shown in Fig. 2, the majority of the
genes either uniquely upregulated by Stx1 or coregulated by
LPS encoded proteins involved in transcriptional regulation,
followed by genes encoding products with unknown functions,
apoptosis, cell signaling, chromatin structure, inflammation,
cell proliferation, cell cycle, and finally cell adhesion. The list-
ing of 149 gene probe sets that were upregulated by Stx1 but
failed one or more of the statistical tests is shown in Table S2
in the supplemental material.
Validation of Stx1 induced upregulation of genes in macro-
phage-like THP-1 cells by real-time RT-PCR. Based on earlier
studies suggesting that Shiga toxins induce the expression of
cytokines and chemokines (13) and trigger signaling cascades
(5), we elected to further analyze the expression of five select
genes involved in transcriptional regulation, inflammation and
cell signaling (Table 2). In order to confirm the microarray
data, real-time RT-PCR was performed. Fold change values
were determined by first normalizing each gene to GAPDH
and then to the untreated control by using the comparative
threshold method (25). The microarray analyses revealed that
Egr-1, COX-2, DUSP1, DUSP5, and DUSP10 were upregu-
lated 10.7-, 3.2-, 6.9-, 3.6-, and 1.7-fold, respectively. We con-
firmed upregulation of these genes by real-time RT-PCR, with
fold-increases of 51 for Egr-1, 3.6 for COX-2, 15.9 for DUSP1,
2.0 for DUSP5, and 2.4 for DUSP10. Differences in fold in-
creases between microarray analysis and real-time RT-PCR
may be due to the different nature of the two techniques; for
example, the two methods require and use different normal-
ization procedures (28). However, the trend of upregulation is
confirmed by both assays.
Egr-1 is upregulated by Stx1 and LPS treatments. Egr-1 is a
zinc finger transcription factor that belongs to a group of early
response genes. Many environmental stimuli including growth
factors, hormones, and neurotransmitters dramatically and
rapidly induce Egr-1 expression. It has been proposed that
Egr-1 couples extracellular signals to long-term responses by
altering expression of genes that are Egr-1 sensitive (48). Egr-1
is known to be a pleiotropic inflammatory transactivator whose
transcriptional activity has been shown to play a major role in
more than 300 target genes, including TNF-, intercellular
adhesion molecule 1 (ICAM-1), macrophage chemoattractant
protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-
1), IL-1, IL-6, transforming growth factor  (TGF-), CD44,
plasminogen activator inhibitor 1, and tissue factor (21, 35).
Interestingly, many of these Egr-1-regulated target genes have
been shown to be induced by Stxs (13–14). To better under-
stand the kinetics of Egr-1 expression induced by treatment
with Stx1 and LPS, macrophage-like THP-1 cells were stimu-
lated for various times, and Egr-1 mRNA and protein levels
were measured by real-time RT-PCR and Western blot anal-
ysis, respectively. Egr-1 mRNA was detected as early as 30 min
(1.7-fold) after stimulation with Stx (400 ng/ml), reaching max-
imum expression by 4 h (52.3-fold). The levels then decreased
but did not return to basal levels, as at 24 h, there was still a
20-fold increase in Egr-1 mRNA expression (Fig. 3A). Upregu-
lated expression of Egr-1 mRNA by LPS (200 ng/ml) was not
detected at the 6-h time point, based on microarray analysis.
However, a more complete analysis of the kinetics of egr-1
induction using real-time RT-PCR suggested that LPS treat-
ment of macrophage-like THP-1 cells induced Egr-1 mRNA
with very different expression kinetics compared to Stx1. Egr-1
mRNA was detected 15 min after stimulation with LPS (17-
fold), reaching maximal expression by 1 h (280-fold) and then
steadily decreasing. There was, however, elevated transcript
expression (13.6-fold) detected after 6 h, the last time point
TABLE 2. Validation by real-time RT-PCR of selected genes
determined to be upregulated by treatment of THP-1
macrophage-like cells with Stx1 (400 ng/ml) or LPS
(200 ng/ml) for 6 h
GenBank
accession no.a Gene
Fold changeb as determined by:
Microarray qRT-PCR
Stx1 LPS Stx1 LPS
NM_001964* Egr1 10.7 1.5 51 13.6
NM_000964* COX2 3.2 44.5 3.6 82.19
NM_004417 DUSP1 6.9 6.1 15.9 62.7
U16996 DUSP5 3.6 21.2 2 1117
N36770 DUSP10 1.7 1.5 2.4 3
a Genes denoted by an asterisk (*) were represented on the microarray by
more than one probe set, and each was determined separately to be significantly
upregulated by Stx1.
b The values shown are means of three or more experiments.
FIG. 2. Genes upregulated by Stx1. The 36 genes uniquely upregu-
lated by Stx1 or coregulated by LPS treatment were categorized by
function.
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collected in these stimulation experiments (Fig. 3B). Thus,
LPS elicited a rapid and extensive increase of Egr-1 mRNA
that decayed very quickly (within 2 h), whereas Stx1 caused a
sustained, lower level of Egr-1 mRNA expression over 24 h.
When cells were treated with both Stx1 and LPS, a combina-
tion of the individual treatment kinetics was observed (Fig.
3C). Egr-1 transcript was detected as early as 15 min (5.2-fold),
increased rapidly peaking at 1 h (202-fold increase) and grad-
ually decreased to a 23-fold increase at 12 h after stimulation.
This was the last time point measured in these experiments
because, as previously shown (12), macrophage-like THP-1
cells treated with both Stx1 and LPS undergo rapid apoptosis.
At the protein level, elevated Egr-1 production was observed
by Western blot analysis at 2 h (2.0-fold) after Stx treatment,
reaching maximum levels at 8 h (3.2-fold) and slowly decreas-
ing to near basal levels by 24 h (Fig. 4A and C). When cells
were stimulated with LPS, elevated Egr-1 protein level was
detected as early as 1 h and peaked at 2 h (27.2-fold), gradually
decreasing to undetectable levels by 6 h (Fig. 4B and D). Thus,
the kinetics of Egr-1 protein production induced by Stx1 or
LPS was well correlated with mRNA induction kinetics, with
the latter preceding protein production.
ERK1/2 signaling is involved in Stx1 induced Egr-1 and
TNF- mRNA expression. It has been shown that activation of
the MEK-ERK1/2 pathway by LPS can induce egr-1 expression
(11). Furthermore, we have shown that Stx1 transiently acti-
vates ERK1/2 signaling in THP-1 cells (5). Therefore, we in-
vestigated the role of ERK1/2 in Stx1 induced Egr-1 mRNA
expression. Cells were treated with the ERK1/2 inhibitor
PD98059 for 1 h before Stx1 stimulation for various times. We
found that treatment with Stx1 plus ERK1/2 inhibitor almost
completely abolished Egr-1 transcript, significantly so at the 2-
and 6-h time points (Fig. 5A). Numerous studies suggest that
nuclear recruitment of NF-B, Egr-1, and c-Jun are required
for full activation of TNF- in macrophages and macrophage-
like cell lines (51, 56). Therefore, the capacity of Stx1 to in-
crease TNF- mRNA production through the ERK1/2-Egr-1
pathway was explored. When THP-1 cells were treated with
Stx1 plus ERK1/2 inhibitor, the TNF- transcript levels
dropped dramatically compared to Stx1-treated cells, a change
in expression that was statistically significant at 6 h after intox-
ication (Fig. 5B).
COX-2 is upregulated by Stx1 and LPS treatments. COX-2
catalyzes the rate-limiting step in the formation of eicosanoids.
COX-2 expression is inducible, and yet the enzyme remains
undetectable in most mammalian tissues under basal condi-
tions. Many stimuli can induce COX-2 expression and produc-
tion such as LPS, cytokines, nitric oxide, growth factors, and
UVB irradiation, among others (52). COX-2 upregulation was
detected in the microarray study in cells treated with Stx1 (400
ng/ml) or LPS (200 ng/ml) for 24 or 6 h, respectively. Using
real-time RT-PCR, we noted a slow and constant increase in
COX-2 transcript expression during the 24-h time course after
Stx1 treatment. Significant increases in COX-2 transcript were
detected after 1 h (1.5-fold) and slowly increased, reaching a
maximum after 24 h (5.3-fold), as shown in Fig. 6A. LPS is
known to be a potent inducer of cox-2 gene transcription (17).
When macrophage-like THP-1 cells were stimulated with LPS,
we observed an increase in COX-2 transcript, but with very
different induction kinetics and quantities compared to Stx1
(Fig. 6B). Increased transcript levels were detected as early as
15 min after LPS stimulation (11-fold) and reached maximum
levels at the 3-h time point (4,407-fold). COX-2 transcript
levels then decreased to an 82-fold induction after 6 h of
FIG. 3. Egr-1 mRNA expression by macrophage-like THP-1 cells. Cells were stimulated with Stx1 (400 ng/ml) (A), LPS (200 ng/ml) (B), or
Stx1LPS (400 and 200 ng/ml, respectively) (C) for different times. Total RNA was isolated, DNase treated, and cDNA synthesized. Quantitative
real-time PCR was performed with primers specific for Egr-1 and GAPDH. Relative expression was calculated by using the CT method. The data
shown are the mean fold induction  the standard error of the mean (SEM) derived from at least three independent experiments. Statistical
significance was calculated by using one-way ANOVA (P values: *, 0.05; **, 0.01).
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treatment. Therefore, we show that while Stx1 caused a slow,
constant increase of low levels of COX-2 expression, LPS trig-
gered a rapid, transient increase of a much greater magnitude.
When cells were treated with both stimulants, we expected to
see a pattern similar to what was observed for the Egr-1 tran-
script, that is, the rapid induction of high levels of mRNA
expression. However, when THP-1 cells were treated with both
Stx1 and LPS, COX-2 mRNA was detected as early as 15 min
(2.6-fold) but peaked at 2 h (721.5-fold) with much less mag-
nitude compared to that seen with the LPS treatment (Fig.
6C), a phenomenon not observed in the Egr-1 transcript. At
longer time points, the fold induction of COX-2 expression was
increased in Stx1LPS-treated cells. For example, at 6 h after
stimulation, COX-2 expression was increased 3.5-fold by Stx1,
86-fold by LPS, and 156-fold by Stx1LPS. Thus, Stx1 ap-
peared to dampen the effect of LPS on the induction of peak
levels of COX-2 mRNA expression in macrophage-like THP-1
cells, but higher levels of COX-2 mRNA expression were
maintained over time when the cells were simultaneously
treated with both bacterial products.
When we studied protein levels of COX-2 in cells treated
with Stx1 we found that COX-2 levels increased as early as 1 h
(2.5-fold) and remained relatively constant, peaking at 6 h
(3.8-fold) and later decreasing slightly (Fig. 7A and C). LPS is
considered a potent activator of COX-2 expression (17). Sur-
prisingly, when we measured protein levels of COX-2 in LPS
FIG. 4. Egr-1 protein levels in macrophage-like THP-1 cells. Cells were stimulated with Stx1 (400 ng/ml; panels A and C) or LPS (200 ng/ml;
panels B and D) for various times. Whole-cell lysates (100 g) were subjected to SDS–4 to 20% PAGE and probed with a polyclonal antibody
against Egr-1. An antibody against actin was used to normalize protein loading. The blots shown in panels A and B are representative of at least
three independent experiments. Panels C and D show the mean fold change  the SEM calculated from densitometric scanning of at least three
individual experiments. Statistical significance was calculated by using one-way ANOVA (P value: *, 0.05; **, 0.01; ***, 0.001).
FIG. 5. Stx1-induced ERK1/2 signaling regulates Egr-1 and TNF- mRNA expression in macrophage-like THP-1 cells. Cells were stimulated
with Stx1 (400 ng/ml) in the presence or absence of the ERK1/2 inhibitor PD 98059 (50 M) for different times. Total RNA was isolated, DNase
treated, and cDNA synthesized. Quantitative real-time PCR was performed using primers specific for Egr-1 (A) and TNF- (B) and normalized
to GAPDH. Relative expression was calculated by using the CT method. The data shown are the fold induction values  the SEM from at least
three independent experiments. Statistical significance was calculated by using two-way ANOVA (P value: **, 0.01; ***, 0.001 [Stx1 versus
Stx1PD98059]).
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treated THP-1 cells, we found similar induction kinetics and
quantities compared to those elicited by Stx1 (Fig. 7B and D).
Thus, for reasons that remain to be explored, the high levels of
COX-2 transcript induced by LPS did not correlate with equiv-
alent increases in COX-2 protein levels.
Eicosanoid production in macrophage-like THP-1 cells
treated with Stx1. COX-2 transforms arachidonic acid (AA) to
eicosanoids. First AA is converted to prostaglandin G2 and H2,
which are then transformed to prostaglandins, prostacyclins or
thromboxanes. Induction of COX-2 leads to the production of
eicosanoids, which may eventually cause an inflammatory re-
action in the host (52). For this reason, we measured the levels
of a key proinflammatory prostaglandin, PGE2, and the vaso-
active eicosanoid thromboxane, TXB2, in culture supernatants
collected from cells stimulated with Stx1 (400 ng/ml) or LPS
(200 ng/ml) for various time points. We found a time-depen-
dent increase of both PGE2 and TXB2 in cells treated with Stx1
(Fig. 8A and B). Levels above baseline were detected after 6 h
(PGE2) and 8 h (TXB2) of treatment and continued to in-
crease, reaching their maximum levels after 24 h. Thus, the
synthesis of PGE2 and TXB2 correlates with COX-2 mRNA
and protein expression/production patterns induced by Stx1
treatment. LPS treatment also resulted in a time-dependent
increase of PGE2 production with a greater magnitude than
Stx1 treatment (Fig. 8C) that mirrored the COX-2 protein
expression pattern seen in Fig. 7D, reaching maximal produc-
tion at 8 h (678 pg/ml).
Dual-specificity phosphatase expression induced by Stx1
and LPS. We have previously shown that Stx1 triggers the
activation of the MAPK cascades JNK, p38, and ERK (5). Also
known as MAPK phosphatases (MKPs), DUSPs are en-
zymes which dephosphorylate and inactivate MAPK iso-
forms in mammalian cells. Significant upregulation of three
DUSPs (DUSP1, -5, and -10) in cells treated with Stx1 was
seen by the microarray analysis and validated by real-time
RT-PCR. The observation that Stx1 induces DUSP transcripts
suggests that signaling pathways to counterbalance MAPK ac-
tivation by Stx1 may be operative in macrophage-like THP-1
cells. Therefore, we analyzed the mRNA kinetics of all three
phosphatases. In cells stimulated with Stx1, DUSP1 mRNA
levels increased as early as 30 min (2.6-fold) and continually
increased, peaking at the 24-h time point (24.6-fold). When
cells were stimulated with LPS, the kinetics of induction was
different from Stx1 treatment; DUSP1 mRNA was detected at 15
min (5.4-fold), peaking at 3 h (154.6-fold), and decreasing slowly
to 62.7-fold at 6 h. When cells were treated with both stimulants,
a biphasic pattern was observed. DUSP1 mRNA was detected as
early as 15 min (6.9-fold), peaking at 3 h (171.8-fold) decreasing
to 57.7-fold at 4 h and peaking again at 12 h with more intensity
than the first peak (501.5-fold) (Table 3).
DUSP5 mRNA expression in cells treated with Stx1, fol-
lowed a similar pattern to DUSP1. Elevated DUSP5 mRNA
was detected later, at 4 h (1.5-fold), steadily increasing until
reaching a maximum of 7.6-fold after 24 h. LPS kinetics were
faster and stronger but also sustained. Transcript was detected
after 15 min of exposure to LPS (4.1-fold), increased in a
time-dependent fashion and peaked after 6 h (1,117-fold),
never decreasing. In cells treated with both Stx1 and LPS,
DUSP5 transcript was detected after 15 min (1.8-fold) and
increased steadily throughout the time course, peaking at 12 h
(3,063-fold) (Table 3).
As for DUSP10 expression in cells treated with Stx1, tran-
FIG. 6. COX-2 mRNA expression by macrophage-like THP-1 cells. Cells were stimulated with Stx1 (400 ng/ml) (A), LPS (200 ng/ml) (B), or
Stx1LPS (400 and 200 ng/ml, respectively) (C) for different times. Total RNA was isolated, DNase treated, and cDNA synthesized. Quantitative
real-time PCR was performed with primers specific for COX-2 and GAPDH. The relative expression was calculated by using the CT method. The
data shown are the mean fold induction  the SEM from at least three independent experiments. Statistical significance was calculated by using
one-way ANOVA (P value: *, 0.05; **, 0.01; ***, 0.001).
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script was detected after only 30 min (1.5-fold) and increased
slowly, reaching its maximum after 24 h (10-fold). LPS was not
a stronger inducer than Stx1 for DUSP10. Furthermore, the
kinetics of DUSP10 induction by LPS was quite different from
other genes analyzed. DUSP10 transcript was not detected
until 1 h after treatment initiation (1.7-fold), slowly increased
until peaking after 5 h (3.2-fold). When cells were treated with
both Stx1 and LPS, we did not observe an additive effect on
FIG. 7. COX-2 protein levels in macrophage-like cells. Cells were stimulated with Stx1 (400 ng/ml; panels A and C) or LPS (200 ng/ml; panels
B and D) for various times. Whole-cell lysates (100 g) were subjected to SDS–4 to 20% PAGE and probed with a polyclonal antibody against
COX-2. An antibody against actin was used to normalize protein loading. The blots shown in panels A and B are representative of at least three
independent experiments. Panels C and D show the mean fold change  the SEM calculated by densitometric scanning of at least three individual
experiments. Statistical significance was calculated by using one-way ANOVA (P value: *, 0.05).
FIG. 8. PGE2 and TxB2 production in macrophage-like THP-1 cells stimulated with Stx1 (400 ng/ml; panels A and B) or LPS (200 ng/ml; panel
C). PGE2 and TxB2 levels were measured in supernatants collected from cells stimulated with Stx1 or LPS for various times by using a sandwich
ELISA. Eicosanoid standards were provided with the kits used. Values are given as pg/ml and are expressed as the mean  the standard error of
three independent experiments. Statistical significance was calculated by using one way ANOVA (P value: *, 0.05).
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DUSP10 transcription as seen in other genes. DUSP10 mRNA
was detected after 15 min and increased slowly, peaking at 12 h
(15.3-fold) (Table 3).
DISCUSSION
We have previously shown that human macrophage-like
THP-1 cells are relatively resistant to the cytotoxic action of
Stx1, with a 50% cytotoxic dose (CD50) of 1.0 g/ml (38).
Furthermore, we used [3H]leucine incorporation experiments
to demonstrate that treatment of THP-1 cells with sublethal
amounts of Stx1 (400 ng/ml) mediated a transient increase in
protein synthesis (7). We showed that much of this increased
synthetic capacity was directed to the production of cytokines
(IL-1, IL-6, and TNF-) and chemokines (IL-8, MIP-1,
MIP-1, MCP-1, and GRO-2) (13, 14). The purpose of the
present study was to more fully evaluate the transcriptional
response of macrophage-like cells in response to Stx1.
We found that 36 genes were upregulated by this treatment,
with 14 genes being uniquely upregulated by Stx1. These genes
fell into the following functional categories (listed in order of
decreasing frequency): transcriptional regulation, unknown
function, apoptosis, cell signaling, chromatin structure, inflam-
mation, cell proliferation, cell cycle, and cell adhesion. A com-
plete listing of these genes is found in Table S1 in the supple-
mental material. Interestingly, no genes were downregulated
by Stx1 treatment of THP-1 cells. In comparison to LPS, Stx1
affected the transcription levels of a relatively limited number
of genes. These findings appear to be consistent with earlier
microarray analyses using Stxs. Keepers et al. (20) performed
microarray analysis on unfractionated murine renal cells treated
with Stx2, LPS, or Stx2LPS and detected, respectively, 136,
737, and 722 significantly expressed genes. In murine cells,
genes uniquely upregulated by Stx2 encoded proteins with
functions related to transcriptional regulation, cell prolifera-
tion, and cell cycle regulation. Matussek et al. (27) treated
human umbilical vein endothelial cells with sublethal amounts
of Stxs for 24 h and showed that 20 genes were upregulated by
Stx1 and 15 genes were upregulated by Stx2. Most of the genes
altered by toxin exposure encoded cytokines and chemokines
(IL-8, CSF2, GRO-1, GRO-2, and GRO-3).
A comparison of toxin-specific gene induction in endothelial
cells revealed interesting differences. The genes encoding the
cytokine IL-6 and the chemokine MCP-1 appeared to be
uniquely activated by Stx2, whereas Stx1 selectively activated
the expression of genes encoding the transcription factors
Egr-1, Fos, and JunB and the phosphatase DUSP1. In accor-
dance with these results, we have shown that both Egr-1 and
DUSP1 are activated in Stx1-treated THP-1 cells. Epidemio-
logical studies suggest that infection with STEC expressing
Stx2 or Stx2 variant toxins constitutes a greater risk for pro-
gression to life-threatening extraintestinal complications (2,
46). It is intriguing to speculate that differences in the capacity
of the toxin types to alter the expression of genes encoding
inflammatory mediators or transcriptional regulators may be
associated with differences in disease progression. However,
more comparative analyses of gene expression using Stx1 and
Stx2 with multiple cell types will be necessary to establish a
correlation between toxin-mediated changes in gene expres-
sion and disease outcome.
It should be noted that the microarray data reported here
were subjected to three independent, stringent statistical algo-
rithms and the biological relevance was measured. Thus, there
is a high level of confidence in the list of genes reported to be
upregulated by Stx1. However, this approach is likely to un-
derestimate the total numbers of genes whose expression may
be altered by Stx1. In this regard, 149 probe sets were filtered
out of the analysis based on failure to meet all of the criteria
for statistical significance, including genes whose expression
has previously been reported to be upregulated by Stxs:
TNF-, IL-8, MIP-1 (CCL3), MIP-1 (CCL4), and GRO-
(CXCL2) (see Table S2 in the supplemental material). Fur-
thermore, the microarray analysis was limited to a single time
point, 6 h of Stx1 (or LPS) stimulation. Our previous analyses
of the kinetics of the THP-1 cell cytokine/chemokine response
to Stx1 suggested that this time point should be near optimal
for transcriptional activation (13–14); however, a more com-
TABLE 3. Dual-specificity phosphatase mRNA expression in differentiated THP-1 cells treated with Stx1 (400 ng/ml), LPS (200 ng/ml), or
Stx1LPS (400 and 200 ng/ml, respectively) for various times
Time
point (h)
Dual-specificity phosphatase mRNA expression (mean fold change  SE)a
Stx LPS StxLPS
DUSP1 DUSP5 DUSP10 DUSP1 DUSP5 DUSP10 DUSP1 DUSP5 DUSP10
Control 0.7  0.2 0.6  0.3 0.8  0.1 0.7  0.4 1.4  0.7 0.7  0.4 0.7  0.30 1.4  0.7 0.8  0.2
0.25 – – – 5.4  3.7 4.1  1.6 0.7  0.1 6.9  2.1 1.8  0.9 1.2  0.1
0.5 2.6  0.8 0.6  0.2 1.5  0.3 50.5  38.8 2.1  1.9 1.0  0.8 43.2  11.0 2.0  0.9 0.9  0.3
1 2.9  0.6 0.8  0.2 1.8  0.5 131.6  56.5 12.8  11.6 1.7  1.4 141.3  16.8 11.2  6.6 1.8  0.4
2 11.8  4.0 1.0  0.1 1.7  0.8 141.2  76.0 137.2  108.4 1.2  0.9 124.4  47.5 234.7  167.0 2.2  0.6
3 – – – 154.6  50.3 420.1  248.5 2.0  0.4 171.8  119.2 839.8  701.6 2.9  1.8
4 18.5  6.0 1.5  0.2 1.9  0.4 77.0  6.5 416.6  198.7 2.0  0.5 57.67  3.3 496.7  323.6 1.8  0.2
5 – – – 57.0  18.4 705.7  95 3.2  0.1 142.3  1.7 730.7  314.8 2.8  0.9
6 15.9  4.1 2.0  0.3 2.4  0.4 62.7  45.3 1,117.0  523.4* 3.0  0.1 170.6  49.9 979.0  499.6 3.5  1.8
8 14.6  3.5 3.2  0.6* 3.6  1.2 – – – 292.7  31.3** 1,214.0  461.4 3.8  0.5
10 19.8  7.3* 3.8  0.7* 3.1  0.7 – – – 235.6  24.0* 1,594.0  489.3 6.9  0.6
12 16.9  5.4 3.3  0.9* 4.2  1.4 – – – 501.5  8.7*** 3,063.0  1119.0* 15.3  3.6*
24 24.6  76.2** 7.6  0.9* 10.0  3.0*** – – – – – –
a –, Data not available. P value: ,0.05; ,0.01; ,0.001 (compared to the control). Means and standard errors are shown based on at least three independent
experiments.
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plete time course of changes in gene expression triggered by
Stx1 will be necessary to fully characterize the macrophage
response to the toxins.
Since the majority of the upregulated genes fell into the
transcriptional regulation category, and Egr-1 expression was
shown to be upregulated by Stx2 in murine kidney cells (20)
and by Stx1 in human endothelial cells (27), we decided to
further explore the expression kinetics of Egr-1 in response to
Stx1, LPS and Stx1LPS treatment. Egr-1 is an immediate-
early transcription factor that is known to play a major role in
regulating the expression of TNF-, ICAM-1, MCP-1, MIP-1,
IL-1, and IL-6, proteins that are known to be produced in
response to Stxs (3, 13–14, 20, 27, 38–39). Thus, signaling
through Egr-1 in macrophages may lead to the production of
cytokines and chemokines, the promotion of tissue damage,
and the induction of leukocyte recruitment and activation in
the various target organs affected by Stxs. We detected upregu-
lated expression of this gene with all treatments, albeit with
different kinetics. Egr-1 mRNA and protein production were
slowly induced by Stx1, compared to LPS, and the peak fold
increase in Egr-1 protein level induced by Stx1 was only 15%
of that induced by LPS. LPS is a well-known stimulator of
Egr-1 expression, and our results showing rapid mRNA and
protein levels are in agreement with previous studies (11).
Patients with bacillary dysentery may be endotoxemic (24) and
those with hemorrhagic colitis may express elevated titers of
antibodies directed against STEC O antigens (18), suggesting
that LPS may access the circulation after intestinal epithelial
barrier damage or perturbation. Therefore, we treated THP-1
cells with Stx1LPS. Treatment of THP-1 cells with both stim-
ulants resulted in a combination of the individual kinetic pro-
files; that is, Egr-1 transcripts were rapidly induced as seen
after LPS treatment, and yet prolonged elevations in transcript
levels were detected, as was the case after Stx1 treatment. This
pattern of gene expression is a phenomenon that has been seen
for other genes induced by Stx1LPS treatment, including
those that code for TNF- and IL-1 (14).
Egr-1 is an 80-kDa phosphoprotein that contains multiple
zinc-finger DNA-binding domains. In response to external
stimuli such as LPS, cytokines, growth factors, hypoxia, or
generation of reactive oxygen intermediates, Egr-1 is translo-
cated to the nucleus and binds to cis-active CG-rich sequences
located in many promoter elements (4). The promoter for the
egr-1 gene contains five sequential serum response elements
(SREs) capable of binding serum response factor and ternary
complex factors (TCFs) such as Elk-1, as well as binding sites
for NF-B, Sp1, and CRE (48). Stimuli that activate the JNK
and p38 MAPK cascades phosphorylate TCFs, which subse-
quently facilitates TCF binding to SREs and egr-1 gene acti-
vation (reviewed in reference 31). We have previously shown
that Stx1 activates the NF-B, JNK, p38, and ERK pathways in
macrophage-like THP-1 cells (5, 39). To link Stx1-induced
ERK activation with signaling through Egr-1 for increased
TNF- expression, we showed that the ERK inhibitor PD
98059 significantly reduced the rapid activation of egr-1 expres-
sion and TNF- production in response to the toxin.
We also explored the expression patterns of COX-2 in re-
sponse to the different treatments. COX-2 catalyzes the rate-
limiting step in the formation of eicosanoids from arachidonic
acid that is released from the plasma membrane by phospho-
lipase A2. COX-2 is inducible and remains undetectable in
most mammalian tissues under basal conditions (52). We
found that Stx1 induced modest (4-fold) increases in COX-2
mRNA and protein levels over a 24-h time course. In contrast,
LPS dramatically increased COX-2 mRNA expression in a
transient manner but elicited levels of COX-2 protein that
were roughly comparable to that elicited by Stx1. The lack of
correlation between LPS-induced COX-2 transcript expression
and protein production in THP-1 cells is currently not under-
stood. Treatment of THP-1 cells with both stimulants resulted
in rapid COX-2 transcript induction similar to that seen with
LPS treated cells; however, the magnitude of induction was
only20% of that induced by LPS alone. This phenomenon of
reduced COX-2 mRNA and protein production was also re-
ported for human glomerular endothelial cells treated with
Stx1LPS compared to LPS alone (41). We also noted re-
duced levels of IL-8 after treatment of THP-1 cells with
Stx1LPS compared to LPS alone (13). These data suggest
that Stxs may selectively dampen some components of the
inflammatory response elicited by LPS when both bacterial
products are present.
To explore the functional consequences of increased COX-2
expression, we measured PGE2 and TxB2 release by macro-
phage-like THP-1 cells treated with Stx1 or LPS. PGE2 is
synthesized by many cell types and is considered the principal
prostaglandin in acute inflammation (33). Thromboxane (TxA2)
is a potent vasoconstrictor and platelet-aggregating eicosanoid
that is produced by platelets and macrophages among other
cell types and is measured indirectly by its stable metabolite
TxB2 (29). We found that Stx1 induces both PGE2 and TxB2
release at relatively late time points after intoxication, while
LPS induces a rapid release of PGE2 that increases in a time-
dependent fashion and with higher magnitude. Adler et al. (1)
and Schmid et al. (41) previously observed TxB2 release in rat
and human glomerular epithelial and endothelial cells treated
with Stx1, and it is noteworthy that renal TxB2 biosynthesis is
increased in children suffering from HUS (50). Although we
did not measure prostacyclin (PGI2) production by THP-1
cells, Stx1 treatment of epithelial and endothelial cells has
been reported to increase PGI2 release (1, 41). The vasodila-
tory and platelet aggregation inhibitory activities of PGI2 are
thought to counterbalance the activities of TxA2. Clinical stud-
ies have reported both increased and decreased serum and
urinary PGI2 levels in HUS patients; however, studies in the
primate model of Stx1-induced acute renal failure did not show
a clear correlation between increased renal PGI2 production
and the development of renal pathology (42).
Finally, we looked at dual specificity phosphatase expression
in THP-1 cells treated with Stx1. These enzymes dephosphor-
ylate and inactivate MAPK isoforms in mammalian cells by
specifically dephosphorylating threonine and tyrosine residues
(32). We have previously shown that in macrophage-like
THP-1 cells treated with Stx1, multiple MAPK pathways are
activated. Prolonged activation of JNK and p38 MAPKs was
found when cells were treated with Stx1 alone, whereas ERK
was only modestly activated for a short period of time (5, 8).
We found that DUSP1 mRNA was rapidly induced by Stx1
treatment. DUSP1 mRNA expression in response to Stx1
treatment has also been shown in Caco-2 and human umbilical
vein endothelial cells (23, 27). Similar to the other genes ana-
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lyzed here, the magnitude of the DUSP1 response was much
higher when cells were treated with LPS and even higher when
both stimulants were used compared to DUSP1 expression
induced by Stx1 alone. To our knowledge, ours is the first study
to show that DUPS5 and DUSP10 transcript expression is
increased in cells treated with Stx1. Like DUSP1, DUSP5
showed similar mRNA expression patterns with all of the treat-
ments, but this was not the case for DUSP10, where Stx1 and
LPS had very similar, rather modest effects on DUSP10 tran-
scription. Higher expression of these phosphatases at later
time points after intoxication corresponds with the decline in
MAPK activation we have previously reported (5, 8), suggest-
ing that DUSPs may act as negative regulators of Stx1-medi-
ated cytokine/chemokine expression. The precise balance of
kinase and phosphatase expression and activation will be ex-
plored further in future studies.
In summary, our data suggest that a select subset of genes is
activated in the macrophage after exposure to purified Stx1.
Over one-third of these genes encode transcriptional regula-
tors. Some of these genes are also activated by the bacterial
outer membrane component LPS, while others appear to be
uniquely activated by Stx1. The microarray data suggest that
macrophages may play an important role in the pathogenesis
of disease caused by Stxs. There is monocyte infiltration into
the kidney during the course of HUS, and elevated levels of
MCP-1 have been detected in the urine of HUS patients.
These findings have been further confirmed using a murine
HUS model (19, 55). The interaction of Stxs with macrophages
(i) increases the expression of the immediate-early transcrip-
tion factor Egr-1, which positively regulates cytokine and che-
mokine expression; (ii) increases the expression of COX-2, an
enzyme involved in the generation of inflammatory and vaso-
active eicosanoids; and (iii) increases the expression of DUSPs
which may disrupt MAPK signaling and downregulate the in-
flammatory response.
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